Mesoblast Limited (ASX:MSB) announced that it has entered into a purchase agreement for a private placement of 10,752,688 common shares at $1.86 per share for gross proceeds of $19,999,999.68 from new investor Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) on July 17, 2018. The transaction is subject to governmental approvals from the People's Republic of China. The company announced that it has received necessary approvals from the investors' directors in their 4th session of the 7th directorate meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 AUD | +1.64% | +21.57% | +200.00% |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+200.00% | 679M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Mesoblast Limited announced that it expects to receive $20 million in funding from Tasly Pharmaceutical Group Co., Ltd.